Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study

OBJECTIVE: This study aimed to report end-of-study results on efficacy and safety of secukinumab 150 mg through 5 years in patients with ankylosing spondylitis (AS; MEASURE 1 extension trial (NCT01863732)). METHODS: After the 2-year core trial, 274 patients receiving subcutaneous secukinumab 150 or...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraliakos, Xenofon, Braun, Juergen, Deodhar, Atul, Poddubnyy, Denis, Kivitz, Alan, Tahir, Hasan, Van den Bosch, Filip, Delicha, Evie-Maria, Talloczy, Zsolt, Fierlinger, Anke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744073/
https://www.ncbi.nlm.nih.gov/pubmed/31565244
http://dx.doi.org/10.1136/rmdopen-2019-001005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744073/
https://www.ncbi.nlm.nih.gov/pubmed/31565244
http://dx.doi.org/10.1136/rmdopen-2019-001005

Ejemplares similares